Navigation Links
Response to preoperative therapy may predict survival in pancreatic cancer patients
Date:5/28/2010

CHICAGO, IL. (May 28, 2010)Cancer of the pancreasa glandular organ that lies behind the stomach and secretes vital enzymes and hormonesseldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

The research, led by Yun Shin Chun, M.D., a surgical oncologist at Fox Chase, will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 6.

Since the 1980s, Fox Chase has been committed to finding better treatments for this intractable disease. In 1986, the Center conducted the first trial in pancreatic cancer of "multimodal" preoperative therapy (the use of more than one kind of treatment, such as chemotherapy and radiation, to kill tumor cells before surgery), and a phase I trial of gemcitabine in the 1990s established the safe dosage for the chemotherapy drug, now widely used in treating the disease.

In the current study, Chun and colleagues wanted to know whether response to preoperative therapy predicts survival in pancreatic adenocarcinomathe most common type of pancreatic cancer. "For many cancersbreast, esophagus, stomach, and colorectal liver metastasesit has been shown that survival is much better in people who have a good pathologic response to preoperative therapymeaning that many tumor cells are killedthan in people who do not have a good pathologic response," says Chun. "But this has not been established in pancreatic cancer; previous studies have shown conflicting results."

In hopes of clearing up the confusion, Chun and colleagues reviewed data on 135 patients who had preoperative therapy and surgery. Fox Chase pathologist Harry Cooper, M.D., examined slides of the patients' tumors and classified their response to preoperative treatment as minor, partial, or major, based on the amount of fibrosis (scarring) in tumor tissue. For patients whose tumors showed major response to preoperative therapy, the median survival was more than five years, compared to seventeen months for those who showed minor response.

Although major response is relatively rareonly 19 percent of patients in the study were so classifiedthe findings give researchers and clinicians important information to build upon. "Going forward, if we can identify molecular factors in tumors associated with a major pathologic response, then we can make important progress in this disease," says Dr. Chun.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Mount Sinai discovers bone marrow plays critical role in enhancing immune response to viruses
2. New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates' Number One Concern: Recovery Time
3. Unique Marketing Approach to the Energy Drink Market Brings Explosive Response
4. Response to vaccines could depend on your sex
5. Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies
6. Babies Responses to Prenatal Stress Differ by Gender
7. A stress-response system in the ear protects against hearing loss
8. Patients whole genome reveals risk of diseases and adverse drug responses
9. Merely seeing disease symptoms may promote aggressive immune response
10. Protein in Breast Tumors May Predict Chemo Response
11. Bodys Response to Foods Smell, Taste Could Be Diabetes Risk Factor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today a ... the Northeast U.S. , GlycoMark is the only clinically available blood test ... a clinically proven one- to two-week measure of hyperglycemic excursions, often related to ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at Moffitt Cancer ... CentrePoint Data Hub in a sample of participants enrolled in an ongoing ... sleep monitoring solutions for the global scientific community. The company’s new CentrePoint Data ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... NuevaCare, a ... as diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades ... persons to bookmark and read organized content on topics such as home care (generally) ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE ... Bloom Burton & Co. Healthcare Investor Conference 2017 at the Sheraton ... Edward Wright , Chief Executive Officer of the Company is scheduled ... CFO, Richard Bear and the Chairman of the Board, ... ...
(Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
Breaking Medicine Technology: